Wellington Management Group LLP Has $70.82 Million Holdings in GSK plc (NYSE:GSK)

Wellington Management Group LLP increased its stake in GSK plc (NYSE:GSK - Free Report) by 10.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,094,105 shares of the pharmaceutical company's stock after buying an additional 190,047 shares during the period. Wellington Management Group LLP owned 0.10% of GSK worth $70,823,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC grew its position in GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after acquiring an additional 278 shares in the last quarter. Sunbelt Securities Inc. raised its stake in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after buying an additional 302 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock worth $232,000 after buying an additional 332 shares in the last quarter. GC Wealth Management RIA LLC grew its holdings in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after purchasing an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC grew its holdings in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after purchasing an additional 389 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Remove Ads

GSK Trading Down 3.1 %

Shares of NYSE GSK traded down $1.06 during mid-day trading on Thursday, hitting $33.42. 1,882,525 shares of the company traded hands, compared to its average volume of 4,580,297. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The stock has a market capitalization of $69.18 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.12 and a beta of 0.56. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The business has a 50 day moving average of $37.55 and a two-hundred day moving average of $36.34.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.71%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK's dividend payout ratio (DPR) is currently 98.74%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GSK shares. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.